Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 9/20 | 0.79 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.79 |
| ▸ | APP | P05067 | 10/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14633002 | 0.88 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL20596127 | 0.88 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL18194573 | 0.88 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL20592376 | 0.88 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL120911 | 0.88 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL23519479 | 0.87 | SPHK1 (0.97) | SPHK1SPHK2 | |
| SCHEMBL13896120 | 0.79 | SPHK1 (0.83) | SPHK1SPHK2 | |
| SCHEMBL21287632 | 0.78 | SPHK1 (0.66) | SPHK1SPHK2APP | |
| SCHEMBL12450365 | 0.77 | SPHK1 (0.79) | SPHK1SPHK2 | |
| SCHEMBL20651369 | 0.76 | SPHK1 (0.63) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372888-B2 | Sphingosine kinase type 1 inhibitors, compositions and processes for using same | ENZO THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100035959-A1 | Novel sphingosine kinase type 1 inhibitors, compositions and processes for using same | ENZO THERAPEUTICS, INC.C/O ENZO BIOCHEM, INC. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035959-A1 | Novel sphingosine kinase type 1 inhibitors, compositions and processes for using same | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885APP 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.